GRITSTONE BIO (GRTSQ) Stock News

Gritstone bio (OTC: GRTSQ) reported updated Phase 2 data for GRANITE, its immunotherapy for first-line microsatellite stable colorectal cancer. The study showed a 27% relative risk reduction of progression or death with GRANITE versus control in all treated population, and a 50% relative risk reduction in the low ctDNA subgroup. As of October 2024, 28% of GRANITE patients and 13% of control patients remain progression-free. The company filed for Chapter 11 bankruptcy on October 10, 2024, and is pursuing bidders for its assets, with a bid deadline of December 4, 2024. Overall survival data is expected in 2H 2025.